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Abstract Various regimens including molecular targeted
agents have been examined in patients with cisplatin
(CDDP)-resistant urothelial cancer (UC). However, some
studies have been stopped owing to the development of
severe adverse events. The main aim of this study was to
examine the anticancer effects, changes in the quality of
life (QoL), and safety of combined therapy of low-dose
gemcitabine, paclitaxel, and sorafenib (LD-GPS) in
patients with CDDP-resistant UC. Twenty patients were
treated with gemcitabine (700 mg/m2 on day 1), paclitaxel
(70 mg/m2 on day 1), and sorafenib (400 mg/day on days
8–22). QoL and pain relief were evaluated using the short-
form survey (SF)-36 for bodily pain and the visual analog
scale (VAS). VAS scores were significantly decreased by
both the second- and third-line therapies (P = 0.012 and
0.028, respectively). The bodily pain score from the SF-36
survey was also significantly (P = 0.012) decreased.
Complete responses, partial responses, and stable disease
were found in 0 (0.0 %), 1 (5.0 %), and 13 patients (65 %),
respectively. The median (interquartile range) period of
overall survival after starting of this therapy was 7 (5–11)
months. Three patients (15.0 %) stopped therapy because
of grade 3 fatigue and hand–foot reactions. LD-GPS ther-
apy was well tolerated by patients with CDDP-resistant
UC. QoL was maintained, and improvements in their pain
levels were found after treatment; pain relief was detected
after third-line therapy. We suggest that this treatment
regimen is worthy of consideration as second- and third-
line therapy for patients with CDDP-resistant UC.
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Introduction
Urothelial cancer (UC) has a high prevalence rate among
the elderly, and UC of the urinary bladder is the seventh
most common cancer worldwide [1]. Bladder cancer
patients with low-grade and low-stage disease are expected
to be cured by local therapy, such as transurethral resec-
tion. In patients with early stage UC of the UT (UTUC),
radical surgery should achieve a complete resection. On the
other hand, outcome and survival of patients with meta-
static and/or recurrent UC is poor. [2–4]. Over the last
20 years, chemotherapies using a cisplatin (CDDP)-based
regimen have been considered the standard treatment
in patients with advanced UC. Presently, combined
chemotherapies, such as gemcitabine (GEM) and CDDP
(GC regimen) and methotrexate, vinblastine, doxorubicin,
and CDDP (MVAC regimen) are known to be the most
effective regimens. However, only a small percentage of
patients are cured completely with these CDDP-based
combined regimens. In fact, the response rates of these
chemotherapies are 40–50 %, and their median survival
period is 14 months [5]. Unfortunately, there is no standard
regimen for second-line therapy. Therefore, many investi-
gators paid special attention to molecular and biological
characteristics of UC cells. As a result, it is well known that
advanced UC commonly has a higher frequency of
changing of cancer-related molecules compared with
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non-muscle-invasive disease. Conversely, the cancer cells
of advanced UC have many target molecules to suppress
their malignant behavior. Therefore, various molecular-
targeting agents have been used for clinical trials for
patients with advanced UC [6]. However, almost all of the
previous clinical trials that have used molecular-targeting
agents have resulted in unsatisfactory efficacy and safety.
In recent years, a combination regimen of low dose of
GEM and paclitaxel (PTX) has been reported to decrease
the pain in patients with CDDP-resistant UC [7]. However,
its anti-carcinogenic effects, including the decreasing of
tumor mass volumes and prolongation of survival, are not
satisfactory. On the other hand, this regimen has been
shown to be safe and well tolerated by UC patients treated
with CDDP-based chemotherapy. We hypothesized that a
modified regimen based on LD-GP therapy plus a molec-
ular-targeting agent may be effective and safe in patients
with CDDP-resistant UC. Sorafenib is an oral multi-kinase
inhibitor that inhibits malignant behaviors, including cell
proliferation and angiogenesis [8–10]. In the present, sor-
afenib is commonly used worldwide for the management of
several cancers, including renal cell carcinoma and hepa-
tocellular carcinoma, because it has higher anticancer
effects and be well tolerated in patients [11, 12].
This is the first report of a clinical trial of combination
therapy with low dose of GEM, PTX, and sorafenib (LD-
GPS) for patients with CDDP-resistant UC. The main aims
of this study were to assess the following three factors: (1)
safety and adverse events (2) maintenance of quality of life
(QOL) after this therapy, and (3) anticancer effects
including the changing of tumor size, survival, and pain
relief. Finally, we demonstrate the usefulness and limita-
tions of combination therapy of LD-GP and sorafenib as
second-line and third-line therapy in patients with
advanced UC.
Patients and methods
Between June 2013 and August 2015, a total of 20 patients
from Nagasaki University Hospital were enrolled into the
study. An adequate bone marrow reserve was mandated for
recruitment, with white blood cells [3000 mm-3, neu-
trophils [1500 mm-3, hemoglobin [8.0 g/dl, and a pla-
telet count[100,000 mm-3 at entry. In addition, adequate
renal and hepatic functions were required, with serum
creatinine \2.0 mg/dl, total bilirubin \1.5 mg/dl, and
aspartate aminotransferase \3 times the upper limit of
normal. Prior to study entry, the Eastern Cooperative
Oncology Group performance status was examined. In this
study, all patients were treated with CDDP-based
chemotherapy as first-line chemotherapy. The main
exclusion criteria were uncontrolled hypertension and
diabetes mellitus, New York Heart Association cardiovas-
cular disease grades III–IV, respiratory failure, active
infection, and incurable malignancies. In addition, patients
with pure adenocarcinoma or squamous cell carcinoma
without transitional cell carcinoma were also excluded.
This study was carried out in accordance with the Decla-
ration of Helsinki and Good Clinical Practice guidelines.
This clinical trial was performed in a single hospital, and
the study design and protocol were approved by the Ethics
Committee (IRB) and Protocol Committee of Nagasaki
University Hospital. All patients provided written informed
consent.
PTX was given at 70 mg/m2 for 3 h by intravenous
infusion on day 1. Similarly, GEM was administered at a
dose of 700 mg/m2 intravenously for 30 min on day 1.
Dexamethasone sodium phosphate (6.6 mg), diphenhy-
dramine hydrochloride (50 mg), and ranitidine hydrochlo-
ride (100 mg) were administered before the administration
of PTX. In addition, sorafenib was administered orally at a
dose of 400 mg once daily on days 8–22. This schedule of
combination chemotherapy with sorafenib was recycled
every 28 days. The continuation of single-agent therapy
with sorafenib or LD-GP was not permitted. During treat-
ment, if an objective response or stable disease were
obtained, the therapy was continued. When the patient or
their family requested the cessation of the therapy, it was
stopped immediately. Toxicities were graded according to
the National Cancer Institute Common Terminology Cri-
teria for Adverse Events, version 3.0. Similar to other
previous studies, sorafenib was withheld until toxicity
decreased to at least grade 2 in case of grade 4 myelo-
suppression and grade 3 toxicity [13].
All patients underwent a computed tomography (CT)
scan and/or magnetic resonance imaging (MRI) to deter-
mine the in-field tumor response. The local response was
assessed using the Response Evaluation Criteria in Solid
Tumors guideline version 1.1. [14]. Based on these
guidelines, complete response (CR) was defined as the
disappearance of all target lesions and reduction of any
pathological lymph nodes to \10 mm in the short axis.
Partial response (PR) was defined as a decrease in the sum
of the longest tumor diameters by at least 30 %. Stable
disease (SD) was defined as neither sufficient shrinkage to
qualify as PR nor sufficient increase in size to qualify as
progressive disease (PD), which was defined as an increase
in the sum of the longest tumor diameters by at least 20 %.
In addition to the relative increase of 20 %, the sum had to
also demonstrate an absolute increase of at least 5 mm. The
appearance of new lesion(s) was also considered disease
progression.
QoL was evaluated using the short-form questionnaire
(SF-36), which comprises 36 questions measuring eight
health scales. All SF-36 scores were linearly transformed to
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a scale of 0–100, where high scores reflect a better QoL.
Pain was rated on a visual analog scale (VAS) of 0–10 (0
indicating no pain and 10 being the most severe pain
imaginable). Data on QoL and pain were collected on the
day before the first cycle was started and 8 weeks after
starting the LD-GP plus sorafenib therapy. Positive pain
relief was defined as a decrease in analgesic consumption
or a decrease in VAS scores and bodily pain scores of the
SF-36 without increasing the dose of analgesics. Regula-
tion of the analgesic dose, including nonsteroidal anti-in-
flammatory drugs and opioids, was performed by an
independent team who were unaware of the study.
Overall survival (OS) was measured from the first day of
LD-GPS therapy to the day of patient death or last patient
contact. Survival was plotted and analyzed using Kaplan–
Meier curves and the log-rank P test. QoL score and
changes in pain and analgesic consumption were evaluated
in 17 patients who received at least two cycles of LD-GPS
therapy. Data are expressed as the median and interquartile
range (IQR). The Mann–Whitney U test was used for the
analysis of continuous variables. The Chi-square test and
Fisher’s exact test were used for categorical comparison of
the data. All statistical tests were two-sided, and signifi-
cance was defined as P\ 0.05. All statistical analyses
were performed on a personal computer with the statistical
package StatView for Windows (version 5.0, Abacus
Concept, Inc., Berkeley, CA).
Results
As shown in Table 1, the median (IQR) age at the start of
LD-GPS therapy was 74 (63–79) years. Eleven patients
(55.0 %) were treated with chemotherapy and surgery,
including transurethral resection. In regard to chemother-
apy, all patients received a CDDP-based regimen including
GC (n = 17, 85.0 %) as 1st-line chemotherapy. A total of
124 cycles were administered, and the median (IQR)
number of treatment cycles per patient was 5 (3–8) cycles.
Among 20 patients, 17 patients (85.0 %) received at least
two cycles of chemotherapy and more than 12 cycles were
given to three patients (15 %). To date, the maximum
number of cycles is 20.
There were no patients with a CR. One (5.0 %) and 13
patients (65.0 %) showed PR and SD, respectively. On the
other hand, six patients (30.0 %) were determined to have
PD. In survival analyses, the median (IQR) period of OS
after starting this therapy was 7 (5–11) months. Survival
rates at 6 and 12 months after starting the therapy were
58.7 and 31.3 %, respectively (Fig. 1a). Similar survival
analyses were performed to distinguish between second-
line and third-line chemotherapies, and median/
IQR periods with second-line therapy (median = 9/
IQR = 6–14 months) had a trend toward being longer than
those with third-line chemotherapy (3/5–7 months). Sur-
vival rates at 6 and 12 months in patients who received this
regimen as second-line chemotherapy (73.3 and 39.3 %)
were higher than that in those receiving it as third-line
therapy (37.5 and 18.9 %). However, Kaplan–Meier sur-
vival curves showed no significant difference between
these patient populations (P = 0.160, Fig. 1b).
As shown in Table 2, VAS scores after the therapy were
significantly (P = 0.001) lower than those before therapy.
In second-line therapy, median/IQR of VAS scores after
therapy (2/2–3) significantly decreased (P = 0.012) com-
pared with their pretreatment levels (3/2–5). Likewise, a
significant decrease was also found in third-line therapy
(5/4–6 to 3/2–3, P = 0.028). Similar data for changes in




Age at start of therapy, age
Median (interquartile range) 74 (63–79)




Primary site, N (%)
Bladder/upper tract 10 (50.0)
Upper urinary tract 10 (50.0)
Sites of tumor, N (%)
Lymph node 19 (95.0)
Primary lesion 9 (45.0)
Lung 8 (40.0)
Soft tissue 4 (20.0)
Bone 3 (15.0)
Others 5 (25.0)
Previous treatment, N (%)
Chemotherapy and operation 11 (55.0)
Chemotherapy 7 (35.0)
Chemotherapy and radiation 2 (10.0)
Performed as second-line or third-line, N (%)
Second 12 (60.0)
Third 8 (40.0)
Priory chemotherapy, N (%)
First-line
Gemcitabine plus cisplatin 17 (85.0)
Other cisplatin-based regimen 3 (15.0)
Second-line (N = 8)
Gemcitabine and paclitaxel 4 (50.0)
Others 4 (50.0)
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VAS expressed as the mean and SD in second-line and
third-line therapies are shown in Fig. 2. A decrease in
analgesic consumption was seen in three patients (17.6 %),
and two patients (11.8 %) had to increase the dose of
analgesic (Fig. 3). Changes in SF-36 scores are shown in
Fig. 3. Similar to the VAS scale, the bodily pain score was
significantly (P = 0.012) decreased by the therapy. In
addition, interestingly, increased bodily pain scores in the
third-line setting were lower than those in the second-line
setting; however, five of six patients had pain relief without
increasing their analgesic consumption (Fig. 3). Role-
physical scores tended to increase with therapy; however,
this difference was not statistically significant (P = 0.103).
On the other hand, the scores for other factors in pre- and
post-treatment evaluations were similar. Finally, according
to data for VAS, SF-36, and analgesic consumption, 11 of
17 patients (64.7 %) were determined to have pain relief.
A summary of the adverse events that occurred in at
least two patients (10 %) and were classified as grade 3 is
shown in Table 2. Hematological events occurred in 11
patients (55.0 %), and two patients required a blood
transfusion for severe anemia. There were no patients who
were treated with antibiotics and granulocyte colony-
stimulating factor (G-CSF) for neutropenia. The most
common non-hematological adverse event was fatigue
(n = 8, 40.0 %). One patient with grade 3 fatigue had to
stop this therapy. Anorexia occurred in five patients
(25.0 %), and two patients (10.0 %) were classified as
grade 3. In regard to sorafenib-related toxicities, although
hypertension and stomatitis were common adverse events
(five patients, 25 %), they were not severe. A hand–foot
Fig. 1 Kaplan–Meier survival curves of overall survival after starting
low-dose gemcitabine, paclitaxel (LD-GP) plus sorafenib therapy.
The median survival period was 7 months (a), which tended to be
longer in the second-line setting compared with that observed in the
third-line setting (b). However, this difference did not reach statistical
significance
Table 2 Changes in quality of
life and pain by treatment
Pre-treatment Post-treatment P value
Short-form (SF)-36 score
Physical functioning 65.0 (46.3–82.5) 65.0 (46.3–76.3) 0.397
Role-physical 56.3 (43.8–76.6) 62.5 (37.5–70.3) 0.103
Bodily pain 42.0 (22.0–72.5) 74.0 (48.5–75.5) 0.012
General health perception 37.0 (31.5–50.0) 32.0 (25.0–48.3) 0.286
Vitality 56.3 (50.0–62.5) 56.3 (43.8–68.8) 0.609
Social functioning 75.0 (46.9–75.0) 75.0 (50.0–90.6) 0.944
Role-emotional 66.7 (50.0–79.2) 66.7 (47.9–83.3) 0.388
Mental health 55.0 (55.0–70.0) 60.0 (45.0–71.3) 0.490
Visual analog scale 4 (3–5) 2 (2–3) 0.001
Data are shown as the median (interquartile range)
Fig. 2 Scores on the visual analog scale of pain were significantly
decreased by the therapy; such pain relief was found in both second-
and third-line settings
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reaction occurred in three patients (15.0 %), and it led to
cessation of the therapy in two patients (10.0 %); the
causes of therapy cessation were severe fatigue and hand–
foot reaction in three patients (Table 3). On the other hand,
two patients (10.0 %) discontinued treatment after one
cycle due to rapid progression of these events; these
patients received this treatment as third-line therapy. In
addition, one patient stopped the therapy after one cycle at
their own request, although they experienced no severe
adverse events.
Discussion
Based on previous in vivo and in vitro studies, various
types of molecular-targeting agents have been used for
advanced UC in clinical trials [15]. However, there is a
general agreement that no single agent or combination
regimen led to a decrease in tumor size and improvement
in the prognosis in these patients. In addition, several
clinical trials of molecular-targeting agents were stopped
during the recruitment phase because of unacceptable
therapy-related toxicities [16]. In regard to sorafenib, sev-
eral clinical studies have been performed in patients with
UC. For example, single-agent sorafenib was used for the
treatment of chemo-naı¨ve UC patients with metastatic
disease [17]. However, this study showed that there was no
objective response and the median time to progression and
survival periods were 1.9 and 5.9 months, respectively.
Another report of second-line sorafenib single-agent ther-
apy also showed that it has minimal anti-tumor activity in
patients with UC [18]. On the other hand, combination
therapy with sorafenib and conventional chemotherapy has
been investigated in clinical trials of patients with
advanced UC. For example, in 2014, the efficacy and safety
of combination therapy of a GC regimen and sorafenib in
patients with locally advanced and/or metastasized UC was
investigated [13]. This combination therapy was performed
as first-line treatment in patients with advanced UC, and
their progression-free survival and OS were 6.3 and
11.3 months, respectively, which were similar to those in
the CG regimen plus placebo group (6.1 and 10.6 months,
respectively). Thus, unfortunately, the efficacy of a single-
agent and combination therapy of sorafenib has not been
shown in clinical studies. In regard to adverse events, a
phase II trial of single-agent sorafenib for 27 patients
showed that 18 % of the patients had to stop the therapy
because of toxicities [18]. In addition, with a combination
regimen of GC and sorafenib, adverse events occurred in
35 of 41 patients (85.4 %) and 25 patients (61.0 %)
experienced severe events [13]. In these previous clinical
studies, sorafenib was orally administered at 400 mg twice
daily [13, 18]. Based on these facts, we decreased the
dosage of sorafenib to 400 mg/day in our regimen.
Our study showed that the median (IQR) OS from the
start of LD-GPS therapy was 7 (5–11) months. A previous
study using second-line therapy with sorafenib for patients
Fig. 3 Changes in the bodily pain score in the short-form question-
naire (SF-36). In a second-line setting, remarkable pain relief was
found in three patients. On the other hand, with the exception of one
patient, bodily pain scores were also improved in the third-line setting
Table 3 Adverse events and reasons for therapy cessation
All grades Grade 3
Hematological, N (%)
Anemia 4 (20.0) 2 (10.0)
Thrombopenia 4 (20.0) 1 (5.0)
Neutropenia 3 (15.0) 0
Non-hematological, N (%)
Fatigue 8 (40.0) 2 (10.0)
Anorexia 5 (25.0) 2 (10.0)
Edema 3 (15.0) 1 (5.0)
Infection 3 (15.0) 1 (5.0)
Hand–foot reaction 3 (15.0) 1 (5.0)
Hypertension 5 (25.0) 0
Alopecia 5 (25.0) 0
Stomatitis 5 (25.0) 0
Fever 4 (20.0) 0
Nausea 3 (15.0) 0
Stomach ache 2 (10.0) 0
N (%)
Therapy cessation 17 85.0
Reasons for cessation
Death 7 35.0
Poor physical condition 3 15.0
Disease progression 3 15.0
Adverse events 3 15.0
Patient’s wish 1 5.0
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with CDDP-resistant UC revealed a median OS of
6.8 months [18]. On the other hand, we previously reported
that the median (IQR) survival rate following second-line
therapy with LD-GP regimen (GEM: 700 mg/m2 and PTX:
70 mg/m2 on days 1 and 8, repeated every 28 days) in
patients with CDDP-resistant UC was 12 (6–22) months
[7]. Thus, the prolongation of survival with LD-GPS reg-
imen was not better than that of other regimens.
Our results showed that the decrease in QoL caused by
the LD-GPS therapy is minimal. One of the most inter-
esting findings in this study is the fact that pain was
improved by this therapy. This finding was confirmed by
two different parameters, including the VAS and bodily
pain score of SF-36. In addition, interestingly, the
improvement in pain relief not only occurred in second-line
therapy, but also in third-line therapy. Based on these
results, we suggest that LD-GPS therapy may be useful as
both second-line and third-line therapy for the control of
QoL, including pain relief.
The frequency and severity of toxicity with this regimen
were relatively low. In fact, no patient required granulocyte
colony-stimulating factor (G-CSF) and platelet transfusion.
Actually, LD-GP therapy resulted in severe leukopenia
requiring treatment with G-CSF and thrombocytopenia
requiring platelet transfusion in 14.3 and 5.7 % of patients,
respectively. In addition, a phase 2 study of sorafenib for
advanced UC patients previously treated with one prior
chemotherapy showed that grade 4 pulmonary embolism
occurred in two of 27 patients (7 %), although our study
population had no patients with embolization [18]. This
phase 2 study also reported that grade 3 fatigue and hand–
foot reaction each occurred in five patients (19 %). While
these two non-hematological toxicities also occurred in our
study population, grade 3 fatigue and hand–foot reaction
only occurred in 10 and 5 % of patients, respectively. On
the other hand, many clinical trials of molecular-targeting
agents, including sunitinib and bevacizumab, have been
reported to have more frequent and severe toxicities [10,
11]. From these facts, when the dosage of sorafenib is
increased to more than 800 mg/day, GP plus sorafenib
therapy may not be tolerated and safe for advanced UC
patients who were previously treated with chemotherapy.
The main limitations of this study are the relatively low
number of patients and the uniformity of patients’ clini-
copathological features. In this study, we paid special
attention to safety and QoL in LD-GPS therapy because no
similar regimen has been described in previous reports. In
recent years, anti-PD-1 treatment is attracting worldwide
attention [19]. However,
On the other hand, we must emphasize the possibility
that a decreased dosage of sorafenib may stimulate the
malignant behavior in patients with UC. That is, in vitro
studies showed that pharmacological concentrations of
sorafenib C3 lM can inhibit migration and proliferation as
well as promote apoptosis; however, low concentrations of
sorafenib (0.1 lM) stimulated migration and proliferation
of bladder cancer cells [20]. In addition, another recent
study also demonstrated that a significant increase in
bladder cancer cell viability was detected at a low con-
centration of sorafenib (2 lM) in vitro [21]. However,
there is no general agreement on whether a low dose of
sorafenib promotes tumor growth and progression in UC.
In fact, in a previous study, a significant increase in
migration and proliferation was observed with 0.1 lM of
sorafenib, but not with 1 lM [20]. In addition, the stimu-
latory effect of 0.1 lM sorafenib was found in RT4 and
T24 cells, but not in J82 cells. Likewise, in the latter study,
an increase in cell viability with 2 lM sorafenib was
observed in T24 cells, but not in VMCub1 cells [21]. Thus,
more detailed studies are necessary to conclude the rela-
tionship between the concentration of sorafenib and the
anticancer effects in UC cells. In fact, when our results
concerning progression and outcomes are compared with
those in other reports using a GP regimen, a negative
influence of low-dose sorafenib in patients with UC was
not noticed. Similarly, other investigators also reported that
the influence of different doses of sorafenib on outcome in
patients with UC was not confirmed [13]. However, we are
concerned that extremely low concentrations of sorafenib
and a variety of factors in the microenvironment sur-
rounding cancer cells may enhance tumor growth and
progression in vivo. We support the opinion that the dose
of sorafenib must be carefully considered when planning
therapeutic regimens including sorafenib in patients with
UC.
In conclusion, this study is the first report of a
prospective phase II trial to investigate the safety, main-
tenance of QoL, changes in pain relief, and anticancer
effects of LD-GPS regimen in patients with CDDP-resis-
tant UC. Our results indicate that this regimen is safe and
well tolerated as second- and third-line therapies. However,
the anticancer effects, including the prolongation of sur-
vival, were similar or less than those with other previous
regimens in a second-line setting. On the other hand, the
improvement in pain relief with this therapy in a third-line
setting was similar to that in a second-line setting. As such,
we support the opinion that LD-GPS therapy is worthy of
consideration for patients with CDDP-resistant UC as both
second- and third-line regimens.
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